PubRank

Stefano Costanzi

Author PubWeight™ 66.16‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Gigantism and acromegaly due to Xq26 microduplications and GPR101 mutation. N Engl J Med 2014 4.00
2 A low-molecular-weight antagonist for the human thyrotropin receptor with therapeutic potential for hyperthyroidism. Endocrinology 2008 2.03
3 Evaluation of small-molecule modulators of the luteinizing hormone/choriogonadotropin and thyroid stimulating hormone receptors: structure-activity relationships and selective binding patterns. J Med Chem 2006 1.71
4 Combined treatment with renin-angiotensin system blockers and polyunsaturated fatty acids in proteinuric IgA nephropathy: a randomized controlled trial. Nephrol Dial Transplant 2008 1.56
5 Facilitating adverse drug event detection in pharmacovigilance databases using molecular structure similarity: application to rhabdomyolysis. J Am Med Inform Assoc 2011 1.44
6 Discovery of novel agonists and antagonists of the free fatty acid receptor 1 (FFAR1) using virtual screening. J Med Chem 2008 1.38
7 A low molecular weight agonist signals by binding to the transmembrane domain of thyroid-stimulating hormone receptor (TSHR) and luteinizing hormone/chorionic gonadotropin receptor (LHCGR). J Biol Chem 2006 1.38
8 Structure-activity relationships of uridine 5'-diphosphate analogues at the human P2Y6 receptor. J Med Chem 2006 1.28
9 Identification of residues important for agonist recognition and activation in GPR40. J Biol Chem 2007 1.28
10 Structural basis of G protein-coupled receptor-G protein interactions. Nat Chem Biol 2010 1.27
11 Bidirectional, iterative approach to the structural delineation of the functional "chemoprint" in GPR40 for agonist recognition. J Med Chem 2007 1.26
12 Low level exposure to cadmium increases the risk of chronic kidney disease: analysis of the NHANES 1999-2006. BMC Public Health 2010 1.25
13 N(6)-alkyl-2-alkynyl derivatives of adenosine as potent and selective agonists at the human adenosine A(3) receptor and a starting point for searching A(2B) ligands. J Med Chem 2002 1.22
14 A virtual screen for diverse ligands: discovery of selective G protein-coupled receptor antagonists. J Am Chem Soc 2008 1.20
15 Structure activity and molecular modeling analyses of ribose- and base-modified uridine 5'-triphosphate analogues at the human P2Y2 and P2Y4 receptors. Biochem Pharmacol 2005 1.18
16 Ligand and structure-based models for the prediction of ligand-receptor affinities and virtual screenings: Development and application to the beta(2)-adrenergic receptor. J Comput Chem 2010 1.13
17 Renal resistive index and long-term outcome in chronic nephropathies. Radiology 2009 1.09
18 Two arginine-glutamate ionic locks near the extracellular surface of FFAR1 gate receptor activation. J Biol Chem 2008 1.09
19 Structural basis of M3 muscarinic receptor dimer/oligomer formation. J Biol Chem 2011 1.06
20 Molecular recognition at purine and pyrimidine nucleotide (P2) receptors. Curr Top Med Chem 2004 1.06
21 Nucleotide analogues containing 2-oxa-bicyclo[2.2.1]heptane and l-alpha-threofuranosyl ring systems: interactions with P2Y receptors. Bioorg Med Chem 2004 1.04
22 Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550). J Med Chem 2008 1.04
23 Defining the nucleotide binding sites of P2Y receptors using rhodopsin-based homology modeling. J Comput Aided Mol Des 2006 1.01
24 Atomistic insights into rhodopsin activation from a dynamic model. J Am Chem Soc 2008 1.00
25 Molecular modeling of the human P2Y2 receptor and design of a selective agonist, 2'-amino-2'-deoxy-2-thiouridine 5'-triphosphate. J Med Chem 2007 0.99
26 Medicinal chemistry and pharmacology of A2B adenosine receptors. Curr Top Med Chem 2003 0.99
27 New insights for drug design from the X-ray crystallographic structures of G-protein-coupled receptors. Mol Pharmacol 2012 0.98
28 Pyrimidine nucleotides with 4-alkyloxyimino and terminal tetraphosphate δ-ester modifications as selective agonists of the P2Y(4) receptor. J Med Chem 2011 0.98
29 Docking-based virtual screening for ligands of G protein-coupled receptors: not only crystal structures but also in silico models. J Mol Graph Model 2010 0.96
30 Structural aspects of M₃ muscarinic acetylcholine receptor dimer formation and activation. FASEB J 2011 0.95
31 Pyrimidine ribonucleotides with enhanced selectivity as P2Y(6) receptor agonists: novel 4-alkyloxyimino, (S)-methanocarba, and 5'-triphosphate gamma-ester modifications. J Med Chem 2010 0.95
32 In silico analysis of the binding of agonists and blockers to the β2-adrenergic receptor. J Mol Graph Model 2011 0.94
33 Prediction of passive blood-brain partitioning: straightforward and effective classification models based on in silico derived physicochemical descriptors. J Mol Graph Model 2010 0.92
34 A2B adenosine receptor blockade inhibits growth of prostate cancer cells. Purinergic Signal 2013 0.91
35 Purine receptors: GPCR structure and agonist design. Mol Interv 2004 0.90
36 Pharmacochemistry of the platelet purinergic receptors. Purinergic Signal 2011 0.90
37 Modeling G Protein-Coupled Receptors: a Concrete Possibility. Chim Oggi 2010 0.89
38 Understanding the structural and functional differences between mouse thyrotropin-releasing hormone receptors 1 and 2. Proteins 2008 0.88
39 Computing highly correlated positions using mutual information and graph theory for G protein-coupled receptors. PLoS One 2009 0.87
40 Development of selective high affinity antagonists, agonists, and radioligands for the P2Y1 receptor. Comb Chem High Throughput Screen 2008 0.86
41 A missense mutation in the seven-transmembrane domain of the human Ca2+ receptor converts a negative allosteric modulator into a positive allosteric modulator. J Biol Chem 2006 0.86
42 Functionalized congeners of P2Y1 receptor antagonists: 2-alkynyl (N)-methanocarba 2'-deoxyadenosine 3',5'-bisphosphate analogues and conjugation to a polyamidoamine (PAMAM) dendrimer carrier. Bioconjug Chem 2010 0.85
43 Activation of the P2Y1 receptor induces apoptosis and inhibits proliferation of prostate cancer cells. Biochem Pharmacol 2011 0.85
44 Unraveling the structure and function of G protein-coupled receptors through NMR spectroscopy. Curr Pharm Des 2009 0.84
45 Molecular Structure of P2Y Receptors: Mutagenesis, Modeling, and Chemical Probes. Wiley Interdiscip Rev Membr Transp Signal 2012 0.84
46 Molecular recognition at adenine nucleotide (P2) receptors in platelets. Semin Thromb Hemost 2005 0.84
47 Agonists and antagonists for P2 receptors. Novartis Found Symp 2006 0.83
48 Functional properties of subunit interactions in human cytidine deaminase. Protein Eng 2003 0.82
49 Purine nucleosides bearing 1-alkynyl chains as adenosine receptor agonists. Curr Pharm Des 2002 0.81
50 Role of tyrosine 33 residue for the stabilization of the tetrameric structure of human cytidine deaminase. Int J Biol Macromol 2010 0.81
51 Structural basis of the selectivity of the beta(2)-adrenergic receptor for fluorinated catecholamines. Bioorg Med Chem 2009 0.81
52 Effects of 5'-phosphate derivatives of 2-hexynyl adenosine and 2-phenylethynyl adenosine on responses of human platelets mediated by P2Y receptors. J Med Chem 2005 0.80
53 Molecular evolution of the transmembrane domains of G protein-coupled receptors. PLoS One 2011 0.80
54 Novel structural and functional insights into M3 muscarinic receptor dimer/oligomer formation. J Biol Chem 2013 0.80
55 Hepatocyte growth factor and transforming growth factor beta1 ratio at baseline can predict early response to cyclophosphamide in systemic lupus erythematosus nephritis. Arthritis Rheum 2006 0.79
56 Action of nucleosides and nucleotides at 7 transmembrane-spanning receptors. Nucleosides Nucleotides Nucleic Acids 2006 0.79
57 Adenine and deazaadenine nucleoside and deoxynucleoside analogues: inhibition of viral replication of sheep MVV (in vitro model for HIV) and bovine BHV-1. Bioorg Med Chem 2002 0.79
58 Design and synthesis of new bicyclic diketopiperazines as scaffolds for receptor probes of structurally diverse functionality. Org Biomol Chem 2005 0.78
59 2- and 8-alkynyl-9-ethyladenines: Synthesis and biological activity at human and rat adenosine receptors. Purinergic Signal 2005 0.78
60 2-ClATP exerts anti-tumoural actions not mediated by P2 receptors in neuronal and glial cell lines. Biochem Pharmacol 2004 0.77
61 Application of Monte Carlo-based receptor ensemble docking to virtual screening for GPCR ligands. Methods Enzymol 2013 0.77
62 Predicting the biological activities through QSAR analysis and docking-based scoring. Methods Mol Biol 2012 0.76
63 Probing GPCR structure: adenosine and P2Y nucleotide receptors. Methods Enzymol 2013 0.75
64 Purine and deazapurine nucleosides: synthetic approaches, molecular modelling and biological activity. Farmaco 2003 0.75
65 Deaza- and deoxyadenosine derivatives: synthesis and inhibition of animal viruses as human infection models. Nucleosides Nucleotides Nucleic Acids 2003 0.75